AA
VIRX

AlphaCentric Advisors’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

AlphaCentric Advisors’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$329K Sell
90,000
-2,402
-3% -$12.8K 0.1% 78
2021
Q3 		$741K Hold
92,402
– – 0.19% 49
2021
Q2 		$1.05M Hold
92,402
– – 0.28% 23
2021
Q1 		$855K Buy
+92,402
New +$963K 0.29% 28

Other funds holding VIRX

RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

AlphaCentric Advisors's VIRX Position: Q4 2021 in Review

AlphaCentric Advisors reduced its Viracta Therapeutics, Inc. Common Stock (VIRX) stake by 2.6% in Q4 2021, selling an estimated $12.8K and leaving 90,000 shares worth $329K. The position accounts for 0.1% of the portfolio, ranked #78.

AlphaCentric Advisors first reported a position in VIRX in Q1 2021 and has held it in 4 quarters since. The position peaked at $1.05M in Q2 2021. 69 funds tracked by Wall St. Rank hold VIRX as of Q4 2021.

  • AlphaCentric Advisors held 90,000 shares of Viracta Therapeutics, Inc. Common Stock worth $329K as of Q4 2021.
  • AlphaCentric Advisors sold 2,402 Viracta Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $12.8K.
  • Viracta Therapeutics, Inc. Common Stock made up 0.1% of AlphaCentric Advisors's portfolio in Q4 2021, its #78 holding.
  • AlphaCentric Advisors first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2021 and has held it in 4 quarters since.
  • AlphaCentric Advisors's Viracta Therapeutics, Inc. Common Stock position peaked at $1.05M in Q2 2021.
  • 69 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2021.

Based on AlphaCentric Advisors's 13F filing for Q4 2021, filed 25 Feb 2022.